MSLN and cancer: Because MSLN is often expressed on the surface of human normal tissues and its nonspecific toxicity is lower [21,22], researchers have designed a variety of therapeutic methods targeting MSLN antigens, such as antitoxins, antibody-based therapy, cancer vaccines and adoptive T-cell therapy.